A new scientific breakthrough may soon offer hope for people affected by Alzheimer’s disease. A group of researchers in Spain ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.